AWM Investment Company’s Black Diamond Therapeutics BDTX Stock Holding History

AWM Investment Company’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.12M	Sell	525,000 -100,000	-16%	-$238K	0.12%	89
2025 Q4	$1.52M	Buy	625,000 +25,000	+4%	+$88.5K	0.15%	93
2025 Q3	$2.27M	Buy	600,000 +100,000	+20%	+$293K	0.21%	84
2025 Q2	$1.24M	Hold	500,000	–	–	0.14%	85
2025 Q1	$775K	Buy	+500,000	New	+$1.05M	0.11%	85

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AWM Investment Company's BDTX Position: Q1 2026 in Review

AWM Investment Company reduced its Black Diamond Therapeutics (BDTX) stake by 16% in Q1 2026, selling an estimated $238K and leaving 525,000 shares worth $1.12M. The position accounts for 0.12% of the portfolio, ranked #89.

AWM Investment Company first reported a position in BDTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.27M in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

AWM Investment Company held 525,000 shares of Black Diamond Therapeutics worth $1.12M as of Q1 2026.
AWM Investment Company sold 100,000 Black Diamond Therapeutics shares in Q1 2026, an estimated $238K.
Black Diamond Therapeutics made up 0.12% of AWM Investment Company's portfolio in Q1 2026, its #89 holding.
AWM Investment Company first reported a position in Black Diamond Therapeutics in Q1 2025 and has held it in 5 quarters since.
AWM Investment Company's Black Diamond Therapeutics position peaked at $2.27M in Q3 2025.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on AWM Investment Company's 13F filing for Q1 2026, filed 15 May 2026.